What\u27s In a Story? The Impact of Data Storytelling On Persuasion

People tell stories to understand the world around them. Life experience fills us with information and knowledge that we store, retrieve, and communicate to inform and persuade decision-making. And this persuasive process is sometimes driven more by emotion than logic. Telling stories allows us to connect emotionally and better persuade others to help them make informed decisions. For business owners, storytelling is essential to communicate with customers, employees, and investors in a way that data and facts alone cannot. This dissertation investigates the relationship between the use of narrative as a construct of data-driven storytelling and its impact on the persuasive effect of data-driven analysis. This research utilizes the Narrative Paradigm theory and Elaboration Likelihood model to measure the impact of narratives, in combination with data and data visualizations, and an individual\u27s need for cognition to measure the persuasive impact of storytelling and narrative in communicating data-driven insights

Creating a Safer Running Experience: Reducing Runner and Vehicular Traffic Incidents

A routine run can turn into a final run in a matter of seconds. Runners and drivers are exposed to a variety of distractions that hinder their ability to safely react to potential incidents. With the help of Augmented Reality and wearable technology, runners can help reduce traffic related incidents by staying focused on the road and their surroundings. This project looks to investigate how AR technology can be leveraged to offer the safest run without diminishing the running user-experience

PROGRESSIVE ENDOSCOPIC APPROACH TO BALLOON DILATION FOR BENIGN ESOPHAGEAL STRICTURES

Benign esophageal strictures are a frequently encountered problem in clinical practice. The management of benign esophageal strictures have slowly evolved over the decades based on “expert opinion.” Despite vast amounts of data about the efficacy and safety of dilation, unfortunately there is no consensus on a systematic and safe approach that is efficient, limits complications and provides long lasting improvement of dysphagia. Our group designed a progressive approach to endoscopic balloon dilation based on tailoring certain technical aspects of the dilation process. Most studies in the literature concluded that endoscopic dilation is safe and effective in relieving dysphagia caused by benign esophageal strictures of various etiologies. There have been few studies that investigated the optimal target of endoscopic dilation of benign esophageal strictures. Our main retrospective secondary study, 27 patients underwent balloon dilation for benign esophageal stricture. Etiology of the esophageal stricture (n=27) included, peptic (n=18, 66.7%), anastomotic (n=4, 14.8%) eosinophilic esophagitis (n=3, 11.1%), post Heller myotomy (n=1, 3.7%) and radiation induced (n=1, 3.7). The diameter of the esophageal stricture ranged from 6mm to 12mm with the most common diameter being 9mm (15%) or 10mm (26%). Most balloon dilations started at 15mm (range 12-15mm, n=26, 59.2%) or \u3e 15mm (n=11, 40.7%) with end dilation of \u3c 15mm \u3e (n=4, 14.8%), 15-\u3c 18mm \u3e (n=7, 25.9%), 18-20mm (n=16, 59.3%). Most patients had 1 to 3 dilations at an interval of every 2-4 weeks to achieve goal diameter of 16-8mm. Many patients with follow up data (77%), all had clinical improvement of their dysphagia. Our study sheds light on the possibility that our novel progressive approach improves the patient’s dysphagia without causing complications, although further investigation is warranted in the form of a prospective randomized trial. Although endoscopic esophageal dilation is considered the best initial therapeutic approach for benign esophageal strictures, the best technique to perform the procedure remains to be determined

The New Oxford Shakespeare Project at IUPUI

poster abstractBecause Shakespeare is the world’s most canonical and most commercially successful secular author, his works have been edited more than any other author. Editions of Shakespeare’s canon are usually based on commercial incentives rather than scholarly preparation; as a result, most editions re-package older ones and do not strive to rethink previous editing in light of more recent scholarship about the Shakespeare canon. The New Oxford Shakespeare editors, staff, and student assistants, however, are revisiting and rethinking the Shakespeare canon from the ground up. Due for publication in October 2016, this exciting new edition of Shakespeare’s Complete Works features the collaborative efforts of an international team of scholars, editors, and IUPUI faculty and students – working alongside each other over a seven year term on IUPUI’s campus. The research involved in this project is cutting edge and completely new to the discipline. We work from archived original printed texts (no manuscript in Shakespeare’s hand exists), and because we are creating the first multi-format, multi-platform Shakespeare edition in history, we approach the work from a three-tiered paradigm, including pedagogy, theatre practice, and computational stylistics. The completed five-volume edition will give readers deeper and multifaceted access to all of Shakespeare’s works: the traditional canon, alternative texts, and collaborative texts. Aiming to satisfy the needs of different users, an old spelling edition will preserve spelling, punctuation, and layout of the earliest texts while a Modern Spelling Edition will utilize recent pedagogical innovations to serve as a 21st century classroom text. The New Oxford Shakespeare will make Shakespeare more accessible to 21st century readers by engaging them through multiple editions and multiple types of media. The New Oxford Shakespeare will empower teacher-scholars to demonstrate Shakespeare’s work in performance and in process. We are the new face of Shakespeare

Gateway Experiences to Engineering Technology: Development of an Introductory Course

The launch of a new Engineering Technology undergraduate degree at a research intensive university prompted collaboration from six different disciplines within the College of Technology. With a flexible curriculum designed to meet existing and future workforce needs, the program of study incorporated both new and revised courses. One of the new courses is a gateway Introduction to Engineering Technology course designed to attract and retain both traditional and nontraditional students. In this introductory course, engineering technology is defined based on the skill set needed for the current and future economy. The gateway course employs a reverse course-content-delivery design whereby students engage traditional lecture-based subject matter in a user-friendly manner that encourages students to revisit lectures on-demand. Students work through a series of at-home assignments in a linear manner, labeled simply as read, watch, and do. These assignments build upon each other to develop both depth and breadth through repeated exposure and analysis of core concepts. This is consistent with learning theory literature, which is replete with studies showing that when students experience expectation failure, followed by a time of thorough and investigative feedback loops, learning gains are increased almost fourfold, from 20–30% to nearly 80% (Karpicke & Roediger, 2008). In addition, based upon student persistence theory (Tinto, 2003), common student experiences are developed for both engineering technology content and the social learning aspect of higher education to create learning-communities for the gateway students (Tinto, 1997)

Interspecific hybridization explains rapid gorget colour divergence in Heliodoxa hummingbirds (Aves: Trochilidae)

Hybridization is a known source of morphological, functional and communicative signal novelty in many organisms. Although diverse mechanisms of established novel ornamentation have been identified in natural populations, we lack an understanding of hybridization effects across levels of biological scales and upon phylogenies. Hummingbirds display diverse structural colours resulting from coherent light scattering by feather nanostructures. Given the complex relationship between feather nanostructures and the colours they produce, intermediate coloration does not necessarily imply intermediate nanostructures. Here, we characterize nanostructural, ecological and genetic inputs in a distinctive Heliodoxa hummingbird from the foothills of eastern Peru. Genetically, this individual is closely allied with Heliodoxa branickii and Heliodoxa gularis, but it is not identical to either when nuclear data are assessed. Elevated interspecific heterozygosity further suggests it is a hybrid backcross to H. branickii. Electron microscopy and spectrophotometry of this unique individual reveal key nanostructural differences underlying its distinct gorget colour, confirmed by optical modelling. Phylogenetic comparative analysis suggests that the observed gorget coloration divergence from both parentals to this individual would take 6.6–10 My to evolve at the current rate within a single hummingbird lineage. These results emphasize the mosaic nature of hybridization and suggest that hybridization may contribute to the structural colour diversity found across hummingbirds

Clinical Implementation of Chromosomal Microarray Analysis: Summary of 2513 Postnatal Cases

BACKGROUND: Array Comparative Genomic Hybridization (a-CGH) is a powerful molecular cytogenetic tool to detect genomic imbalances and study disease mechanism and pathogenesis. We report our experience with the clinical implementation of this high resolution human genome analysis, referred to as Chromosomal Microarray Analysis (CMA). METHODS AND FINDINGS: CMA was performed clinically on 2513 postnatal samples from patients referred with a variety of clinical phenotypes. The initial 775 samples were studied using CMA array version 4 and the remaining 1738 samples were analyzed with CMA version 5 containing expanded genomic coverage. Overall, CMA identified clinically relevant genomic imbalances in 8.5% of patients: 7.6% using V4 and 8.9% using V5. Among 117 cases referred for additional investigation of a known cytogenetically detectable rearrangement, CMA identified the majority (92.5%) of the genomic imbalances. Importantly, abnormal CMA findings were observed in 5.2% of patients (98/1872) with normal karyotypes/FISH results, and V5, with expanded genomic coverage, enabled a higher detection rate in this category than V4. For cases without cytogenetic results available, 8.0% (42/524) abnormal CMA results were detected; again, V5 demonstrated an increased ability to detect abnormality. Improved diagnostic potential of CMA is illustrated by 90 cases identified with 51 cryptic microdeletions and 39 predicted apparent reciprocal microduplications in 13 specific chromosomal regions associated with 11 known genomic disorders. In addition, CMA identified copy number variations (CNVs) of uncertain significance in 262 probands; however, parental studies usually facilitated clinical interpretation. Of these, 217 were interpreted as familial variants and 11 were determined to be de novo; the remaining 34 await parental studies to resolve the clinical significance. CONCLUSIONS: This large set of clinical results demonstrates the significantly improved sensitivity of CMA for the detection of clinically relevant genomic imbalances and highlights the need for comprehensive genetic counseling to facilitate accurate clinical correlation and interpretation

Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921

PURPOSE Bosutinib is approved for adults with chronic myeloid leukemia (CML): 400 mg once daily in newly diagnosed (ND); 500 mg once daily in resistant/intolerant (R/I) patients. Bosutinib has a different tolerability profile than other tyrosine kinase inhibitors (TKIs) and potentially less impact on growth (preclinical data). The primary objective of this first-in-child trial was to determine the recommended phase II dose (RP2D) for pediatric R/I and ND patients. PATIENTS AND METHODS In the phase I part of this international, open-label trial (ClinicalTrials.gov identifier: NCT04258943), children age 1-18 years with R/I (per European LeukemiaNet 2013) Ph+ CML were enrolled using a 6 + 4 design, testing 300, 350, and 400 mg/m$^{2}$ once daily with food. The RP2D was the dose resulting in 0/6 or 1/10 dose-limiting toxicities (DLTs) during the first cycle and achieving adult target AUC levels for the respective indication. As ND participants were only enrolled in phase II, the ND RP2D was selected based on data from R/I patients. RESULTS Thirty patients were enrolled; 27 were evaluable for DLT: six at 300 mg/m$^{2}$, 11 at 350 mg/m$^{2}$ (one DLT), and 10 at 400 mg/m$^{2}$ (one DLT). The mean AUCs at 300 mg/m$^{2}$, 350 mg/m$^{2}$, and 400 mg/m$^{2}$ were 2.20 μg h/mL, 2.52 μg h/mL, and 2.66 μg h/mL, respectively. The most common adverse event was diarrhea (93%; ≥grade 3: 11%). Seven patients stopped because of intolerance and eight because of insufficient response. Complete cytogenetic and major molecular response to bosutinib appeared comparable with other published phase I/II trials with second-generation TKIs in children. CONCLUSION Bosutinib was safe and effective. The pediatric RP2D was 400 mg/m$^{2}$ once daily (max 600 mg/d) with food in R/I patients and 300 mg/m$^{2}$ once daily (max 500 mg/d) with food in ND patients, which achieved targeted exposures as per adult experience